Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review
Autor: | Jamshid Tabeshpour, Zahra Oskouei, Mehri Bemani Naeini, Narges Hedayati |
---|---|
Rok vydání: | 2021 |
Předmět: |
Drug
Berberine media_common.quotation_subject Drug Evaluation Preclinical Biological Availability Pharmacology law.invention chemistry.chemical_compound Nutraceutical Lycopene Randomized controlled trial law Diabetes mellitus medicine Diabetes Mellitus Humans media_common Randomized Controlled Trials as Topic business.industry medicine.disease Combined Modality Therapy Metformin Bioavailability Treatment Outcome chemistry Cardiovascular Diseases Dietary Supplements Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
Zdroj: | European journal of pharmacology. 913 |
ISSN: | 1879-0712 |
Popis: | Nutraceuticals are principally extracted from natural products that are frequently safe and well-tolerated. Lycopene and berberine are natural plants with a wide range of beneficial effects including protective activities against metabolic disorders such as diabetes and cardiovascular diseases. These compounds might be considered technically more as a drug than a nutraceutical and could be prescribed as a product. However, further studies are needed to understand if these supplements could affect metabolic syndrome outcomes. Even if nutraceuticals exert a prophylactic activity within the body, their bioactivity and bioavailability have high interindividual variation, and precise assessment of biological function of these bioactive compounds in randomized clinical trials is critical. However, these reports must be interpreted with more considerations due to the low quality of the trials. The aim of this paper is to bring evidence about the management of cardiovascular diseases and diabetes through the use of nutraceuticals with particular attention to lycopene and berberine effectiveness. |
Databáze: | OpenAIRE |
Externí odkaz: |